Non-Small Cell Lung Cancer Therapy
New non-small cell lung cancer therapy study findings have been published by scientists at University of North Carolina, Lineberger Comprehensive Cancer Center
Published in Drug Law Weekly, June 9th, 2009
New research, 'A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC),' is the subject of a report. According to recent research from the United States, "This trial investigated the efficacy and safety of weekly cetuximab combined with two different schedules of paclitaxel/carboplatin for stage IIIB/IV non-small-cell lung cancer (NSCLC). A total of 168 patients with previously untreated stage IIIB/IV NSCLC were randomized to arm A, cetuximab (400 mg/m2 day 1 followed by weekly 250 mg/m2) + paclitaxel (Taxol) (225 mg/m2)/carboplatin (AUC6) day 1 every 3 weeks or arm B, same...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
Source: Drug Law Weekly (2009-06-09)
More Articles from Drug Law Weekly
- Addiction Medicine
New CASA* Report Finds Federal, State and Local Governments Spend Almost Half a Trillion Dollars a Year on Substance Abuse and Addiction - Adverse Drug Reactions
Researchers from Teikyo University, Medical Department discuss findings in adverse drug reactions - Angiology
New findings reported from S.S. Agarwal and co-authors describe advances in angiology - Bureau of Alcohol, Tobacco, Firearms and Explosives
Two Subjects Arrested for Solicitation to Commit Capital Murder - Burke, Mahoney & Wise
$12 Million Settlement in Birth Injury Lawsuit Against OSF Healthcare, Announces Burke, Mahoney & Wise - Campaign for Tobacco-Free Kids
New Maine Poll: Voters Strongly Support FDA Regulation of Tobacco Products - More from this issue of Drug Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
